Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely…

Overview of attention for article published in Frontiers in Pediatrics, February 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 1 X post from an account with 275 followers.

One-year #canakinumab therapy was found to be potentially effective as second-line #biologictherapy after discontinuation of #tocilizumab in patients with #sJIA https://t.co/vRORCVAkJz #DataViz #visualabstract #JIA #arthritis #juvenilearthritis @Novartis

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.